Salem Radio Network News Tuesday, September 21, 2021

Audio

Pfizer to buy another drugmaker focused on potential cancer treatments

Download

Pfizer is spending more than $2 billion in cash to buy another drugmaker focused on potential cancer treatments

VERBATIM: New York-based Pfizer says it will pay $18.50 for each share of Trillium Therapeutics, or more than double the stock’s 60-day weighted average price. Trillium has no products on the market. Its potential treatments include biologics that aim to prime a patient’s immune system to detect and destroy cancer cells. Its two lead candidates are in early-stage testing and focus on hematology. That includes blood, bone marrow and lymph node cancers like leukemia or lymphoma…JH reporting.

 

Editorial Cartoons

View More »

Steve Breen
Thu, Sep 16, 2021

X CLOSE